Clinical Trial Update: Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cladribine given with simultaneous or delayed rituximab for hairy cell leukemia; results have been posted as of 2025-08-08.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Cladribine (cladribine)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hairy Cell Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-08